FDA approves Gilead cancer gene therapy American Cancer Society, Analysts, Approvals, CAR-T Therapy, Costs, Diffuse Large B-Cell Lymphoma (DLBCL), FDA, FDA/Regulatory, Gene Therapy, Immune Cells, Large B-Cell Lymphoma, M&A, Non-Hodgkin Lymphoma, Pricing, Shares, T-Cells U.S. regulators approved a new therapy for a type of lymphoma, which was developed by Gilead Sciences Inc.’s Kite Pharma. Read more October 18, 2017/by Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 Reuters Health https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png Reuters Health2017-10-18 18:06:102017-10-19 13:20:27FDA approves Gilead cancer gene therapy
